• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Santaris Pharma A S - Product Pipeline Review - Q4 2010 Product Image

Santaris Pharma A S - Product Pipeline Review - Q4 2010

  • ID: 1446266
  • November 2010
  • 45 pages
  • GlobalData

Santaris Pharma A S – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Santaris Pharma A/S - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Santaris Pharma A/S - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Santaris Pharma A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, READ MORE >



List of Tables
List of Figures
Santaris Pharma A/S Snapshot
Santaris Pharma A/S Overview
Key Information
Key Facts
Santaris Pharma A/S – Research and Development Overview
Key Therapeutic Areas
Santaris Pharma A/S – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Santaris Pharma A/S – Pipeline Products Glance
Santaris Pharma A/S Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Santaris Pharma A/S–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Santaris Pharma A/S – Drug Profiles
SPC2996
Product Description
Mechanism of Action
R&D Progress
SPC3649
Product Description
Mechanism of Action
R&D Progress
EZN2968
Product Description
Mechanism of Action
R&D Progress
EZN3042
Product Description
Mechanism of Action
R&D Progress
PCSK9-inhibitors
Product Description
Mechanism of Action
R&D Progress
SPC4955
Product Description
Mechanism of Action
R&D Progress
SPC5001
Product Description
Mechanism of Action
R&D Progress
Santaris Pharma A/S – Pipeline Analysis
Santaris Pharma A/S – Pipeline Products by Therapeutic Class
Santaris Pharma A/S Pipeline Products By Target
Santaris Pharma A/S – Pipeline Products by Molecule Type
Santaris Pharma A/S – Recent Pipeline Updates
Santaris Pharma A/S – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 22, 2010: Santaris Pharma Initiates Phase II Clinical Trial With Miravirsen For Treatment Of Hepatitis C Virus
Apr 26, 2010: Santaris Advances SPC5001 Into Drug Development For Treatment Of High Cholesterol
Apr 26, 2010: Santaris Advances SPC5001 Into Drug Development For Treatment Of High Cholesterol
Dec 03, 2009: Santaris Announces The Development Of SPC3649 For The Treatment Of Hepatitis C Virus (HCV) Infections In Chimpanzees
Jun 04, 2009: LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs Of Clinical Benefit
May 28, 2008: Santaris Pharma Begins Human Clinical Testing Of The World’s First MicroRNA SPC3649
Dec 19, 2007: GlaxoSmithKline And Santaris Pharma Enter Global R&D Alliance To Discover Develop And Commercialize RNA Antagonists As Novel Antivirals
Oct 30, 2007: Enzon Initiates Second Phase I Study Of Its HIF-1 Alpha Antagonist
Jun 11, 2007: Santaris Pharma Shows Strong Phase I/II Data In CLLSPC2996
Apr 18, 2007: Santaris Pharma Presents Positive Preclinical Data On SPC2996 At The American Association For Cancer Research
Financial Deals Landscape
Santaris Pharma A/S, Deals Volume Summary, 2004 to YTD 2010
Santaris Pharma A/S, Deals Summary By Region, 2004 to YTD 2010
Santaris Pharma A/S, Deals Summary, 2004 to YTD 2010
Santaris Pharma A/S Detailed Deal Summary
Venture Financing
Santaris Pharma Secures $30 Million In Series C Financing
Equity Offering
Santaris Pharma Completes Private Placement Of $5 Million
Shire Enters Into Research Agreement With Santaris Pharma
Wyeth Pharmaceuticals Enters Into An Agreement With Santaris Pharma
GlaxoSmithKline Enters Into An Agreement With Santaris Pharma
Enzon Pharmaceuticals Signs Agreement With Santaris Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS